诺和诺德与礼来争夺GLP-1口服药市场，备战Medicare医保覆盖

• 输出包含未在情报源中出现的具体时政主体表述，已通过FactGuard协议处理

1. 核心事实剥离

• 一句话事件本质：两大GLP-1巨头Novo Nordisk与Eli Lilly将竞争战场从注射剂延伸至口服药片，并向Medicare覆盖的老年群体展开推销攻势〔SRC:"Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors